Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
NCT ID: NCT04012411
Last Updated: 2026-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
135 participants
INTERVENTIONAL
2020-03-03
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Several pathophysiological mechanisms have been evoked, including an alteration of the signaling pathway of the Brain Derived Neurotrophic Factor (BDNF), a neurotrophic factor involved in the survival of neurons (striatal and hippocampal) and synaptic plasticity. BDNF is synthesized at the level of cortical neurons and transported, through the axonal transport in which the Htt is involved, to the nerve endings; it's then secreted in response to excitatory synaptic activity, especially at the level of glutamatergic synapses. Besides, at the postsynaptic level it binds with great specificity to TrkB receptors (tropomyosin-related kinase receptors B) with a neuroprotective effect on dendritic and axonal growth and an increase in synaptic plasticity, especially at the level of the striatum and the hippocampus.
BDNF is decreased in the brain of animal models, as well as in patients with HD; the alteration of this pathway would occur in the early stages of the disease.
In the context of concomitant multiple treatments, the BNDF pathway may be one of the therapeutic targets of HD.
Moreover, in HD it remains essential to detect biological markers representative of the different pathogenic pathways that can be tested in vivo in humans to confirm the hypotheses developed at the level of basic research; these biomarkers could subsequently become biomarkers of disease progression and/or biomarkers of therapeutic efficacy of potential targeted treatments.
Therefore, this study aims to characterize potential biomarkers of the BNDF pathway in plasma and CSF in subjects with HD and to confirm the importance of this pathogenic mechanism in vivo in humans.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinicopathological MRI and CSF Correlates in Huntington's Disease.
NCT05534139
31P-MRS and Huntington Disease
NCT01359774
Synaptic Density and Progression of Huntington's Disease.
NCT04701580
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
NCT05224115
Metabolomic Study in Huntington's Disease (METABO-HD)
NCT03296176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Main objective: To evaluate BDNF in cerebrospinal fluid as a potential marker of the BDNF-TrkB signaling pathway in vivo in HD patients at a symptomatic stage.
* Secondary objectives: i) Evaluate plasma BDNF in subjects with HD; ii) Study the correlation between BDNF in CSF and BDNF in plasma; iii) Study the correlation between markers of the BDNF pathway and clinical severity, multimodal brain MRI parameters, and relevant markers of evolution of HD; iv) Confirm the increase of Tau and NFL (Neurofilament Light Chain) markers in plasma and in CSF, as markers of neuronal degeneration, in subjects with HD ; v) Test the TrkB assay in the CSF of patients with HD
* Inclusion Criteria. General inclusion criteria: age ≥ 18 years old; national health insurance cover. Patient inclusion criteria: genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1); written informed consent; patient agreement for LP, if requested. Control inclusion criteria: previous LP for medical reason; agreement for inclusion in a biobank for research purposes.
* Exclusion Criteria. General exclusion criteria: subject protected by law, under curatorship or guardianship. Patients exclusion criteria: too severe HD, according to the clinician's judgment, possibly making difficult to perform cognitive evaluation or MRI; contraindications to brain MRI; contraindications to LP; inability to give informed consent. Control exclusion criteria: presence of a neurodegenerative of inflammatory central nervous system disease.
* Inclusion period: 48 months
* Duration of participation for each patient: 123 days maximum
* Total research duration: 64 months
* Plan of the study. Patients group: in 90 patients with HD, the investigators will perform: a collection of the main anamnestic and clinical data; a blood test for the determination of plasmatic BDNF, Tau and NFL and the genotyping of the Val66Met polymorphism of the BDNF gene; multimodal brain MRI with volumetry, diffusion tensor, functional MRI of rest; a measurement of the severity of Huntington's disease and Total Functional Capacity scales; neuropsychological tests (SDMT, STROOP test, Trail Making Test (TMT) A and B, digit span). In a subgroup of 45 patients, the investigators will also perform a lumbar puncture for the determination of BDNF, Tau, NFL and TrkB in CSF. Control Group: 45 controls will be selected from the samples present in the existing Biobank with CSF and plasma samples available in Montpellier, France. MRI data will be centralized and processed by the Imaging Institute I2FH Montpellier University Hospital.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with LP
Huntington's disease patients who agreed to have LP
Brain MRI
Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
Lumbar Punction
Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
Blood sample
Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
Cognitive evaluation
Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
Patient without LP
Huntington's disease patient with contraindication to LP or refusal to have LP
Brain MRI
Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
Blood sample
Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
Cognitive evaluation
Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
Control Group
Retrospective study with biologic samples of patients without Huntington's disease
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brain MRI
Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
Lumbar Punction
Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
Blood sample
Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
Cognitive evaluation
Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* national health insurance cover
* genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1)
* written informed consent
* only for patients "with lumbar puncture (LP)": patient agreement for LP
* anterior LP for medical reason with consent for biobank "Neuro" with following samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL cerebrospinal fluid
* information and non-opposition for the finality of this biobank
* paired by age with a patient (+/- 5 years difference)
Exclusion Criteria
* Huntington's disease stage too Evolved that may interfere with cognitive evaluations or MRI
* contraindications to brain MRI
* only for patients "with LP": contraindications to LP
* incapacity to give informed consent
* neurodegenerative of inflammatory central nervous system pathology
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL19_0081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.